Abstract ZD6474 [N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)
methoxy] quinazolin-4-amine] is a potent, po active, low molecular weight inhibitor of kinase …

There is evidence that vascular endothelial growth factor (VEGF) contributes to solid tumor
growth through the promotion of both angiogenesis and tumor vascular permeability. To …

Angiogenesis is crucial for maintaining the supply of oxygen and nutrients required to
support solid tumour growth. Inhibitors of tumour blood vessel formation are therefore being …

Background:: ZD6474 selectively inhibits the tyrosine kinase activity of vascular endothelial
growth factor receptor and epidermal growth factor receptor. The safety, tolerability and …

Inhibition of vascular endothelial growth factor-A (VEGF) signaling is a promising therapeutic
approach that aims to stabilize the progression of solid malignancies by abrogating tumor …

Purpose: The purpose of this study was to examine the antitumor effects of the novel
vascular targeting agent ZD6126 and to use histology, CD31 immunohistochemistry, and …

Purpose: Vascular endothelial growth factor (VEGF) is a major mitogen for endothelial cells
and enhances vascular permeability. Enhanced VEGF secretion is found in human cancers …

Purpose ZD6126 is a novel vascular-targeting agent that induces selective effects on the
morphology of endothelial cells by disrupting the tubulin cytoskeleton. This leads to cell …

Abstract PTK787/ZK 222584 (1-[4-chloroanilino]-4-[4-pyridylmethyl] phthalazine succinate)
is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases …

Physiological differences between tumor and normal vasculature provide a target for drug
discovery. In particular, the immature nature of tumor vasculature may render it intrinsically …